https://sms.carm.es/ricsmur/handle/123456789/17867 2026-05-27T15:58:43Z https://sms.carm.es/ricsmur/handle/123456789/26525 La Verdadera Historia de la Anatomía Perdida de Eustaquio (1520-1574) y sus Implicaciones Temporales Moreno-Egea, Alfredo; Moreno-Latorre, Carlos; Moreno-Latorre, Alfredo 2025-01-01T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/26524 Análisis Contextual del Plagio más Famoso de la Historia de la Medicina: Govard Bidloo versus William Cowper Moreno-Egea, Alfredo; Moreno-Latorre, Carlos; Moreno-Latorre, Alfredo 2025-01-01T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/26521 Criterios Beers versus STOPP. Posibles implicaciones de la adaptación española de los criterios de Beers Pastor-Cano, Josep; Aranda-García, Ana; Gascón-Cánovas, Juan-José; Rausell-Rausell, Víctor-José; Tobaruela-Soto, Mariana 2017-01-01T00:00:00Z https://sms.carm.es/ricsmur/handle/123456789/26518 Uso de Ataluren en españa: incoherencias administrativas y aspectos éticos implicados Pacheco-López, Pilar; Meroño-Saura, María-Antonia; Aranda-García, Ana Duchenne muscular dystrophy is a rare genetic disease with only ataluren like pharmaceutical treatment available. This drug received a conditional authorization by the European Medicines Agency (EMA) in 2014, meaning that it was commercially available while waiting for more solid results that demonstrate the efficacy and safety. Currently, the authorization still maintains the "conditional" modality, and the actual health benefits of the drug still remain unclear. In Spain, ataluren is not financed by the National Health System. The decision of non-financing has generated a heated debate, especially because in those patients who se treatment were started prior to the non-financing decision the drug has continued being funded. This controversial situation encompasses complex aspects of pharmaceutical and health management related to scientific evidence, the motivations of regulatory agencies and the pharmaceutical industry in the processes of drug investigation and authorization. Furthermore, as the center of the debate, some pillars of bioethics such as justice and equity, as well as certain legal principles, such as the protection of minors, are involved. 2021-01-01T00:00:00Z